Results 21 to 30 of about 49,888 (287)

The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy

open access: yesAntioxidants, 2021
Nonarteritic anterior ischemic optic neuropathy (NAION) is one of the most common acute optic neuropathies that affect the over 55-year-old population. NAION causes the loss of visual function, and it has no safe and effective therapy. Bardoxolone methyl
Jia-Ying Chien   +4 more
semanticscholar   +1 more source

Anterior ischemic optic neuropathy in a patient with papilledema from idiopathic intracranial hypertension

open access: yesAmerican Journal of Ophthalmology Case Reports, 2020
Patients may lose vision in idiopathic intracranial hypertension from worsening papilledema and optic nerve dysfunction. Acute vision loss may also occur in this context from anterior ischemic optic neuropathy.
Jingyi Ma, Jonathan A. Micieli
doaj   +1 more source

Nonarteritic Anterior Ischemic Optic Neuropathy following COVID-19 Vaccination: Consequence or Coincidence

open access: yesCase Reports in Ophthalmological Medicine, 2021
To report a patient with nonarteritic anterior ischemic optic neuropathy (NA-AION) occurring soon after the COVID-19 vaccination. A 55-year-old woman presented with a 4-day history of inferior visual field disturbance in the right eye 7 days after ...
Rika Tsukii, Yuka Kasuya, S. Makino
semanticscholar   +1 more source

Hyperhomocysteinemia in bilateral anterior ischemic optic neuropathy after conventional coronary artery bypass graft: a case report

open access: yesJournal of Medical Case Reports, 2018
Background The incidence of anterior ischemic optic neuropathy after coronary artery bypass graft procedures ranges from 1.3 to 0.25%. The mechanisms of anterior ischemic optic neuropathy after cardiovascular procedures remain undefined but many systemic
A. Niro   +3 more
doaj   +1 more source

Impending anterior ischemic optic neuropathy with elements of retinal vein occlusion in a patient on interferon for polycythemia vera. [PDF]

open access: yes, 2012
We describe the course and likely pathophysiology of impending anterior ischemic optic neuropathy (AION) and retinal vein occlusion in a 56-year-old man with polycythemia vera managed with interferon alpha for 2 years.
Hirsch, Louis K   +2 more
core   +1 more source

COVID-19 Vaccine-Associated Optic Neuropathy: A Systematic Review of 45 Patients

open access: yesVaccines, 2022
We provide a systematic review of published cases of optic neuropathy following COVID-19 vaccination. We used Ovid MEDLINE, PubMed, and Google Scholar.
Ayman G. Elnahry   +6 more
doaj   +1 more source

Adverse reactions of amiodarone [PDF]

open access: yes, 2019
Adverse drug reaction is defined by the World Health Organization as any response to a drug that is noxious and unintended and occurs at a dose normally used in man.
Calvosa, Leonardo   +5 more
core   +1 more source

Radial optic neurotomy as a treatment for anterior ischemic optic neuropathy secondary to optic disc drusen

open access: yesGMS Ophthalmology Cases, 2014
[english] Importance: Radial optic neurotomy (RON) was first described by Opremcak as a treatment for patients with central retinal vein occlusion (CRVO).
Pinxten, Isabel, Stalmans, Peter
doaj   +1 more source

Pseudo Foster Kennedy Syndrome secondary to uncontrolled hypertension and diabetes mellitus: A case report

open access: yesMedical Journal of Dr. D.Y. Patil University, 2014
Pseudo-Foster Kennedy Syndrome is described as unilateral optic disc swelling with contra lateral optic atrophy in the absence of an intracranial mass causing compression of the optic nerve.
Kavita R Bhatnagar   +3 more
doaj   +1 more source

A Female Patient with Down Syndrome and Low-Penetrance Leber's Hereditary Optic Neuropathy. [PDF]

open access: yes, 2014
We present the case of a 19-year-old female with a history of Down syndrome (DS) who was referred to our neuro-ophthalmology clinic for evaluation of Leber's hereditary optic neuropathy (LHON).
Frousiakis, Starleen E   +3 more
core   +3 more sources

Home - About - Disclaimer - Privacy